niacinamide has been researched along with Ureteral Obstruction in 5 studies
nicotinamide : A pyridinecarboxamide that is pyridine in which the hydrogen at position 3 is replaced by a carboxamide group.
Ureteral Obstruction: Blockage in any part of the URETER causing obstruction of urine flow from the kidney to the URINARY BLADDER. The obstruction may be congenital, acquired, unilateral, bilateral, complete, partial, acute, or chronic. Depending on the degree and duration of the obstruction, clinical features vary greatly such as HYDRONEPHROSIS and obstructive nephropathy.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Sorafenib, which has been used extensively for the treatment of renal cell cancer and advanced hepatocellular carcinoma (HCC), has also been shown to have antifibrotic effects in liver fibrosis." | 7.83 | Sorafenib Inhibits Renal Fibrosis Induced by Unilateral Ureteral Obstruction via Inhibition of Macrophage Infiltration. ( He, C; Li, Q; Liu, C; Liu, Q; Ma, W; Tao, L; Wang, X; Xue, D; Zhang, J; Zhang, W, 2016) |
| "Eight-week-old rats were subjected to unilateral ureteral obstruction (UUO) and were intragastrically administered sorafenib, while control and sham groups were administered vehicle for 14 or 21 days." | 7.81 | Sorafenib ameliorates renal fibrosis through inhibition of TGF-β-induced epithelial-mesenchymal transition. ( Chen, Z; Duan, Z; Fu, R; Ge, H; Gui, B; Han, J; Jia, L; Ma, X; Ou, Y; Tian, L; Wang, L, 2015) |
| "Sorafenib, which has been used extensively for the treatment of renal cell cancer and advanced hepatocellular carcinoma (HCC), has also been shown to have antifibrotic effects in liver fibrosis." | 3.83 | Sorafenib Inhibits Renal Fibrosis Induced by Unilateral Ureteral Obstruction via Inhibition of Macrophage Infiltration. ( He, C; Li, Q; Liu, C; Liu, Q; Ma, W; Tao, L; Wang, X; Xue, D; Zhang, J; Zhang, W, 2016) |
| "Eight-week-old rats were subjected to unilateral ureteral obstruction (UUO) and were intragastrically administered sorafenib, while control and sham groups were administered vehicle for 14 or 21 days." | 3.81 | Sorafenib ameliorates renal fibrosis through inhibition of TGF-β-induced epithelial-mesenchymal transition. ( Chen, Z; Duan, Z; Fu, R; Ge, H; Gui, B; Han, J; Jia, L; Ma, X; Ou, Y; Tian, L; Wang, L, 2015) |
| "Renal interstitial fibrosis is a common pathological feature in progressive kidney diseases currently lacking effective treatment." | 1.51 | Nicotinamide reduces renal interstitial fibrosis by suppressing tubular injury and inflammation. ( Cai, J; Dong, Z; Liu, Z; Shu, S; Tang, C; Wang, Y; Zheng, M, 2019) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 2 (40.00) | 2.80 |
| Authors | Studies |
|---|---|
| Zhang, W | 2 |
| Rong, G | 1 |
| Gu, J | 1 |
| Fan, C | 1 |
| Guo, T | 1 |
| Jiang, T | 1 |
| Deng, W | 1 |
| Xie, J | 1 |
| Su, Z | 1 |
| Yu, Q | 1 |
| Mai, J | 1 |
| Zheng, R | 1 |
| Chen, X | 1 |
| Tang, X | 1 |
| Zhang, J | 2 |
| Takahashi, R | 1 |
| Kanda, T | 1 |
| Komatsu, M | 1 |
| Itoh, T | 1 |
| Minakuchi, H | 1 |
| Urai, H | 1 |
| Kuroita, T | 1 |
| Shigaki, S | 1 |
| Tsukamoto, T | 1 |
| Higuchi, N | 1 |
| Ikeda, M | 1 |
| Yamanaka, R | 1 |
| Yoshimura, N | 1 |
| Ono, T | 1 |
| Yukioka, H | 1 |
| Hasegawa, K | 1 |
| Tokuyama, H | 1 |
| Wakino, S | 1 |
| Itoh, H | 1 |
| Zheng, M | 1 |
| Cai, J | 1 |
| Liu, Z | 1 |
| Shu, S | 1 |
| Wang, Y | 1 |
| Tang, C | 1 |
| Dong, Z | 1 |
| Jia, L | 1 |
| Ma, X | 1 |
| Gui, B | 1 |
| Ge, H | 1 |
| Wang, L | 1 |
| Ou, Y | 1 |
| Tian, L | 1 |
| Chen, Z | 1 |
| Duan, Z | 1 |
| Han, J | 1 |
| Fu, R | 1 |
| Ma, W | 1 |
| Tao, L | 1 |
| Wang, X | 1 |
| Liu, Q | 1 |
| Li, Q | 1 |
| He, C | 1 |
| Xue, D | 1 |
| Liu, C | 1 |
5 other studies available for niacinamide and Ureteral Obstruction
| Article | Year |
|---|---|
Nicotinamide N-methyltransferase ameliorates renal fibrosis by its metabolite 1-methylnicotinamide inhibiting the TGF-β1/Smad3 pathway.
Topics: Animals; Cells, Cultured; Fibrosis; Kidney; Male; Mice; Mice, Inbred C57BL; Niacinamide; Nicotinamid | 2022 |
The significance of NAD + metabolites and nicotinamide N-methyltransferase in chronic kidney disease.
Topics: Animals; Female; Fibrosis; Humans; Male; Methionine; Mice; NAD; Niacinamide; Nicotinamide N-Methyltr | 2022 |
Nicotinamide reduces renal interstitial fibrosis by suppressing tubular injury and inflammation.
Topics: Animals; Apoptosis; Cell Line; Chemokine CCL2; Disease Models, Animal; Fibrosis; Inflammation; Inter | 2019 |
Sorafenib ameliorates renal fibrosis through inhibition of TGF-β-induced epithelial-mesenchymal transition.
Topics: Actins; Animals; Apoptosis; Cadherins; Cell Line; Disease Models, Animal; Epithelial-Mesenchymal Tra | 2015 |
Sorafenib Inhibits Renal Fibrosis Induced by Unilateral Ureteral Obstruction via Inhibition of Macrophage Infiltration.
Topics: Animals; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antineoplastic Agents; Cell Adhesi | 2016 |